Navigation Links
Avalon Ventures Expands Collaboration with GSK and Launches Seventh New Company at COI Pharmaceuticals

SAN DIEGO, Nov. 9, 2015 /PRNewswire/ -- Avalon Ventures today announced that Avalon and GSK are expanding their collaboration to fund and launch early-stage life science companies in San Diego. The collaboration is now worth up to a potential additional $60 million in combined funding and earn-outs per company if the company develops marketed products.  Under the terms of the expanded collaboration, initially established in April 2013, Avalon and GSK will create and fund additional companies through the development of clinical candidates.  Companies will also receive operational support, a fully equipped R&D facility and an experienced leadership team through COI Pharmaceuticals, the Community Of Innovation established by Avalon Ventures.

"The commitment by GSK has allowed us to move with unprecedented speed in transitioning concepts and ideas into functioning companies addressing unmet clinical needs," said Jay Lichter, Ph.D., managing director of Avalon Ventures and president of COI Pharmaceuticals. "The newest, Iron Horse Therapeutics, is pioneering a novel approach to ALS, a disease in critical need of solutions."

"Avalon Ventures and COI Pharmaceuticals foster the type of innovative thinking that the pharmaceutical industry needs," said Lon Cardon, Senior Vice President, Alternative Discovery & Development at GSK. "The entrepreneurial and nimble companies we have founded in collaboration with Avalon will continue to build GSK's portfolio of innovative therapeutics."

Iron Horse Therapeutics, the seventh company launched to date under the Avalon-GSK collaboration, is researching and developing novel treatments for ALS that modulate the activity of a protein called EphA4.  ALS patients with reduced EphA4 expression or activity have less severe disease and live longer.  Interfering with EphA4 signaling protects motor neurons from degeneration, and, in ALS animal models, this approach has been shown to prolong survival and decrease disease severity.

Proprietary small molecule inhibitors of EphA4 were identified in the laboratory of Maurizio Pellecchia, Ph.D., Professor of Translational Research at the Sanford Burnham Prebys Medical Discovery Institute.  This technology was exclusively licensed from the Sanford Burnham Prebys Medical Discovery Institute to Iron Horse Therapeutics.

As with the other companies founded under the collaboration, Iron Horse will receive up to $10 million in Series A financing and R&D support from Avalon and GSK as well as R&D and mentoring support through COI Pharmaceuticals.

The collaboration between Avalon Ventures and GSK previously has launched Sitari Pharma, Silarus Therapeutics, Thyritope Biosciences, Adrenergics, Inc., Cadherx Therapeutics, and Calporta Therapeutics.

Under the collaboration, GSK has the option to acquire each of the companies when a clinical candidate is identified.  However, if GSK does not elect to exercise this option, Avalon will retain its ownership in the company, and the company will be free to enter into other strategic transactions.

About COI Pharmaceuticals
COI Pharmaceuticals is an unconventional venture-pharma entity that provides life science inventors with an environment where entrepreneurial and scientific risks are encouraged and rewarded. This Community of Innovation (COI) was established in 2013 to support companies funded through a collaboration between Avalon Ventures and GSK as well as existing Avalon portfolio companies.  COI provides the intellectual capital to launch companies, a fully-equipped R&D infrastructure and industry mentors prepared to leverage their expertise to help entrepreneurial scientists succeed. COI is located in La Jolla, California.  For more information, please visit:

About Avalon Ventures
Avalon Ventures is a venture capital firm that has founded and/or funded more than 127 information technology and life sciences companies. The firm is passionate about backing talented entrepreneurs seeking to build market-leading companies. Throughout the firm's 32-year tenure, Avalon's long-standing and successful focus has been on seed and early-stage companies. All Avalon partners are seasoned entrepreneurs with experience in company formation, operations and value creation in the life science and tech sectors. Avalon's current fund, launched in 2015, continues the firm's tradition of pursuing disruptive ideas in ever changing markets.  For more information, please visit:


SOURCE COI Pharmaceuticals, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Sitari Pharmaceuticals, First Company Launched Through Avalon Ventures-GlaxoSmithKline Collaboration, Raises up to $10 Million Series A Financing and R&D Support
2. Avalon Ventures and GSK Launch Three New Companies with Series A Financing and R&D Support as Part of Ongoing Successful Collaboration
3. Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures
4. UM Ventures Announces Collaboration Between UM School Of Medicines Dr. Frank Robb and Fina Biosolutions
5. Velocity Pharmaceutical Development and Remeditex Ventures Announce Collaboration Agreement and Initial Co-Investment
6. Syneron Medical And Unilever Ventures Create Iluminage Beauty, A Global Joint Venture In Home Beauty Devices
7. Leonhardt Ventures Cal-X Stars Business Accelerator Raising $15 million
8. Howard Leonhardt of Leonhardt Ventures to Present at World Stem Cell Summit December 6th
9. Pappas Ventures Promotes Scott Weiner to Partner
10. Atonarp Inc. Raises $8M Series A Round Led by Walden Riverwood Ventures
11. ADM Tronics Joins Triotech Ventures Technology Consortium
Post Your Comments:
(Date:7/2/2020)... NIGUEL, Calif. (PRWEB) , ... July 02, 2020 ... ... fastest-growing real estate franchisors, is hosting a four-part health series on its live ... communities in which they live and work. The series includes special guests and ...
(Date:7/1/2020)... ... 01, 2020 , ... Lumeda Inc. (“Lumeda”), a ... formation of its Scientific Advisory Board with the appointment of a panel of ... to support company development and introduction of its PDT products to the clinic. ...
(Date:6/28/2020)... ... June 27, 2020 , ... CPAP Store USA, known for its one ... respiratory devices, is growing and expanding at a rapid rate. Today, CPAP store USA ... - CPAP Store Dallas, located at 3920 Rosemeade Parkway, Suite 150, Dallas, Texas 75287. ...
Breaking Medicine Technology:
(Date:7/1/2020)... ... July 01, 2020 , ... Dexur’s analysis of Medicare ... Hospital , Porter Adventist Hospital , and Sky Ridge Medical Center ... Knee Replacement. Dexur’s value analysis tracks a patient’s episode of care from the date ...
(Date:7/1/2020)... Texas (PRWEB) , ... July 01, 2020 , ... ... announced today that it has been selected by Codiak BioSciences to support its ... PODs will provide the cleanroom infrastructure for the drug substance and product manufacturing ...
(Date:6/28/2020)... ... June 26, 2020 , ... Recovery from ... premier residential addiction treatment center, proudly announces that it has reopened to serve ... for recovery in a world affected by Covid-19. , When social-distancing guidelines changed ...
(Date:6/28/2020)... ... June 28, 2020 , ... World Allergy Organization ... Allergy Week, from June 28 to July 4, 2020, to the importance of ... short for “coronavirus disease 2019”, is a disease spreading around the world caused ...
(Date:6/24/2020)... DULUTH, Minn. (PRWEB) , ... June 24, 2020 , ... ... important problem with connectivity for telemedicine and remote communications. We knew it had to ... to be simple, and that it just has to work. , We are proud ...
Breaking Medicine News(10 mins):